Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparil oral tablets versus topical gel versus placebo for temporomandibular joint disorder
ACTRN12615000310561Phase 2Recruiting
- Sponsor
- Hawler Medical University
- Start
- Dec 2014
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of escin in temporomandibular disorder (TMD) (4 arms), sponsored by Hawler Medical University. Primary endpoints: Global assessment of efficacy and compliance, Pain intensity and maximal comfortable mandibular opening and 1 more. Started Dec 2014; status: recruiting.
02
Drugs
escin
03
Conditions
temporomandibular disorder (TMD)
Beyond the preview
Go deeper on ACTRN12615000310561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000310561.